The 5- and 10-year OS rates for patients with MEN1-related gastrinoma were 83% and 65%, respectively, significantly lower compared to MEN1 patients without gastrinoma [82]. The gene discussed is MEN1; the disease is gastrin-producing neuroendocrine tumor.